Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.12.5955

Burden of Hepatocellular Carcinoma in Asia  

Fazeli, Zeinab (Student's Research Commitee, Shahid Begeshti University of Medical Sciences)
Pourhoseingholi, Mohamad Amin (Gastroenterology and Liver Diseases Research Center, Shahid Begeshti University of Medical Sciences)
Vahedi, Mohsen (Department of Epodemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences)
Zali, Mohammad Reza (Gastroenterology and Liver Diseases Research Center, Shahid Begeshti University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.12, 2012 , pp. 5955-5958 More about this Journal
Abstract
Hepatocellular carcinoma (HCC), the sixth most prevalent cancer worldwide, continues to have high prevalence in many countries of Asia. The main challenge is the high prevalence of chronic hepatitis and aflatoxin, for example in China. HBV vaccination should be the major preventive tactic in Asian countries. The burden of HCC is low in Iran because most cases are due to HBV and this infection was less common. Although in Iran, a mass vaccination program started in 1993, its impact on decreasing the burden of HCC due to HBV can only be expected in future decades.
Keywords
Hepatocellular carcinoma; burden; Asia;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Noh DK, Choi KS, Jun JK, et al (2012). Factors associated with attending the national cancer screening program for liver cancer in Korea. Asian Pac J Cancer Prev, 13, 731-6.   DOI
2 Okuda K (1992). Hepatocellular carcinoma: Recent progress. Hepatology, 5, 948-63.
3 Oshima A, Tsukuma H, Hiyama T, et al (1984). Follow-up study of HBsAg-positive blood donors with special reference to effect of drinking and smoking on development of liver cancer. Int J Cancer, 34, 775-9.   DOI
4 Park JW, Kim CM (2005). Epidemiology of heptocellular carcinoma in Korea. Korean J Hepatol, 11, 303-10.
5 Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.   DOI   ScienceOn
6 Parkin DM, Whelan SL, Ferlay J, et al (2002). Cancer Incidence in Five Continents IARC Scientific Publications No. 155, vol. VIII. Lyon: IARC Press.
7 Pourhoseingholi MA, Fazeli Z, Zali MR, Alavian SM (2010). Burden of hepatocellular carcinoma in Iran; Bayesian projection and trend analysis. Asian Pac J Cancer Prev, 11, 859-62.
8 Qian GS, Ross RK, Yu MC, et al (1994). A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, people's republic of China. Cancer Epidemiol Biomarkers Prev, 3, 3-10.
9 Siddique I, El-Naga HA, Memon A, et al (2004).CLIP score as a prognostic indicator for Hepatocellular carcinoma: experience with patients in the Middle East. Euro J Gastro Hepatol, 16, 675-80.   DOI   ScienceOn
10 Sin HR, Lee CU, Park HJ, et al (1996). Hepatitis B and C virus, for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol, 25, 933-40.   DOI   ScienceOn
11 Shamszad M, Farzadgan H (1982). Hepatitis B related cirrhosis and hepatocellular carcinoma in Iran. J Iranian Med Council, 8, 238.
12 Sun CA,Wu DM, Lin CC, et al (2003). Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol, 157, 674-82.   DOI   ScienceOn
13 Taylor-Robinson SD, Foster GR, Arora S, et al (1997). Increase in primary liver cancer in the UK, 1979-1994. Lancet, 350, 1142-3.
14 Teo EK, Fock KM (2001). Hepatocellular Carcinoma: An Asian Perspective. Dig Dis, 19, 263-8.   DOI   ScienceOn
15 Yang GH, Wang JF, Wan X, et al (2005). Quantitative analysis of factors affected mortality trend in Chinese, 2002. Zhonghua Liu Xing Bing Xue Za Zhi, 26, 934-8.
16 Yoshimi I, Sobue T (2003). Mortality trend of liver cancer in Japan: 1960-2000. Jpn J Clin Oncol, 33, 202-3.
17 You SL ,Yang HI, Chen CJ (2004). Seropositivity of hepatitis B e antigen and hepatocellular carcinoma. Ann Med, 36, 215-24.   DOI   ScienceOn
18 Yu MC, Yuan, J-M, Govindarajan S, Ross RK (2000). Epidemiology of hepatocellular carcinoma. Can J Gastroenterol, 14, 703-9.
19 World Health Organization (2007). Cancer. http://www.who.int/mediacentre/factsheets/fs297/en/.
20 Huang JQ, Zheng GF, Lai CL, et al (2011). Risk of liver cancer in patients with hepatitis B or C. Hong Kong Med J, 17, 41-3.
21 IARC (1987). Monographs, Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs, vol. 1-42, supplement 7. Lyon: IARC Press.
22 Kao JH, Chen DS (2005). Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int, 25, 696-703.   DOI   ScienceOn
23 Kao JH, Tsai SL, Chen PJ, et al (1994). A clinicopathologic study of chronic non-A, non-B (type C) hepatitis in Taiwan: comparison between posttransfusion and sporadic patients. J Hepatol, 21, 244-9.   DOI   ScienceOn
24 Kao JH, Chen DS (1999). Hepatocellular carcinoma in Taiwan: progress in the past decade 1988-1997. In: Leong ASY, Liew CT, Lau JWY, Johnson PJ, eds. Hepatocellular Carcinoma: Contemporary Diagnosis, Investigation and Management. London: Arnold, 235-50.
25 Kim SR, Kudo M, Hino O, et al (2008). Epidemiology of hepatocellular carcinoma in Japan and Korea. A review. Oncology, 75, 13-6.   DOI
26 Kumar V, Fausto N, Abbas A (editors) (2003). Robbins & Cotran Pathologic Basis of Disease (7th ed.). Saunders. pp. 914-7.
27 Koriech O, Al-Kuhaymi R (1994). Profile of cancer in Riyadh armed forces hospital. Ann Saudi Med, 14, 187-94.
28 Lai EC, Lau WY (2005). The continuing challenge of hepatic cancer in Asia. Surgeon, 3, 210-5.   DOI   ScienceOn
29 Law MG, Roberts SK, Dore GJ, Kaldor JM (2000). Primary hepatocellular carcinoma in Australia, 1978-1997: Increasing incidence and mortality. Med J Aust, 173, 403-5.
30 Liu Y, Chang CC, Marsh GM, Wu F (2012). Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer, 48, 2125-36.   DOI   ScienceOn
31 Liu Y, Wu F (2010). Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect, 118, 818-24.   DOI   ScienceOn
32 Makimoto K, Higuchi S (1999). Alcohol consumption as a major risk factor for the rise in liver cancer mortality rates in Japanese men. Int J Epidemiol, 28, 30-4.   DOI
33 Merat S, Malekzadeh R, Rezvan H, Khatibian M (2000). Hepatitis B in Iran. Arch Iran Med, 3, 192-201.
34 Matsuda T, Saika K (2012). Trends in liver cancer mortality rates in Japan, USA, UK, France and Korea based on the WHO mortality database. Jpn J Clin Oncol, 42, 360-1.   DOI   ScienceOn
35 McGlynn KA, London WT (2005). Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol, 19, 3-23.   DOI
36 McGlynn KA, Tsao L, Hsing AW, et al (2001). International trends and patterns of primary liver cancer. Int J Cancer, 94, 290-6.   DOI   ScienceOn
37 Ming L, Thorgeirsson SS, Gail MH, et al (2002). Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology, 36, 1214-20.   DOI   ScienceOn
38 Cai L, Chongsuvivatwong V, Geater A (2008). Changing pattern of premature mortality burden over 6 years of rapid growth of the economy in suburban south-west China: 1998-2003. Public Health, 122, 478-86.   DOI   ScienceOn
39 CDC (2003). Global progress toward universal childhood hepatitis B vaccination, 2003. MMWR, 52, 868-9.
40 Chang MH, Chen CJ, Lai MS, et al (1997). Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med, 336, 1855-9.   DOI   ScienceOn
41 Chen JG, Zhang SW (2011). Liver cancer epidemic in China: past, present and future. Semin Cancer Biol, 21, 59-69.   DOI   ScienceOn
42 Colombo M, Kuo G, Choo Q, et al (1989). Prevalence of antibodies to hepatitis C virus in Italian patients with Hepatocellular carcinoma. Lancet, 2, 1006-8.
43 Chen DS (1993). From hepatitis to hepatoma: lessons from type B viral hepatitis. Science, 262, 369-70.   DOI
44 Chuang SC, La Vecchia C, Boffetta P (2009). Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett, 286, 9-14.   DOI   ScienceOn
45 Chen DS (1995). Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Princess Takamatsu Symp, 25, 27-32.
46 Chen CH, Chen YY, Chen GH, et al (2004). Hepatitis B virus and hepatocarcinogenesis: a 9 year retrospective cohort of 13676 relatives with hepatocellular carcinoma. J Hepatol, 40, 653-9   DOI   ScienceOn
47 Chen CJ, Yu MW, Liaw YF (1997). Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol, 12, 294-308.   DOI   ScienceOn
48 Deuffic S, Poynard T, Buffa L, Valleron AJ (1998). Trends in primary liver cancer. Lancet, 351, 214-5.
49 Di Bisceglie AM, Lyra AC, Schwartz M, et al (2003). Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol, 98, 2060-3.
50 Drinking in the United States: main findings from the 1992 National Longitudinal Alcohol Epidemiology Survey (NLAES) (1998). US Alcohol epidemiology Data Reference Manual, Volume 6, First Edition. NIAAA/NIH NIH Publication No. 99-3519.
51 Fallot G, Neuveut C, Buendia MA (2012). Diverse roles of hepatitis B virus in liver cancer. Curr Opin Virol, 2, 467-73.   DOI
52 Gomaa AI, Khan SA, Toledano MB, et al (2008). Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol, 14, 4300-8.   DOI   ScienceOn
53 Gwack J, Park SK, Lee EH, et al (2011). Hepatitis B vaccination and liver cancer mortality reduction in Korean children and adolescents. Asian Pac J Cancer Prev, 12, 2205-8.
54 Anand R (2002). Aflatoxins, in: IARC monograph on the evaluation of carcinogenic risks to humans, vol. 82, in: Some Traditional Herbal Medicines Some Mycotoxins, Naphthalene and Styrene, McGraw-Hill, New York, 171-300.
55 Hajiani E, Masjedzadeh R, Hasehemi J, et al (2005). Risk factors for hepatocellulr carcinoma in southern Iran. Saudi Med J, 26, 974-7.
56 Han KH, Ahn SH (2005). How to predict HCC development in patents with chronic B-viral liver disease? Intervirology, 48, 23-8.   DOI   ScienceOn
57 Alavian SM, Fallahian F, Lankarani KB (2007). The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis, 16, 403-6.
58 Bae JM, Jung KW, Won YJ (2002). Estimation of cancer deaths in Korea for the upcoming years. J Korean Med Sci, 17, 611-5.   과학기술학회마을   DOI
59 Blumberg BS (2010). Primary and secondary prevention of liver cancer caused by HBV. Front Biosci (Schol Ed), 1, 756-63.